Logo

Colorectal Cancer

News and reporting on colorectal cancer.

Mainz Biomed Licenses mRNA Biomarkers for Colorectal Cancer

Mainz said it will potentially integrate the biomarkers into its ColoAlert detection test for colorectal cancer.

Mainz Biomed, Ganzimmun Diagnostics Partner to Commercialize Colorectal Cancer Test

Mainz's ColoAlert test combines fecal immunochemistry with an analysis of cell DNA from stool to detect colorectal cancer at the earliest stages.

Freenome Raises $300M in Series D Financing

The company will use the funding to support commercialization of its blood-based colorectal cancer detection test and to fuel expansion to other tumor types.

HER2 Treatments See New Milestones in Colorectal Cancer, With Liquid Biopsy Identifying Responders
Premium

New data from a Japanese Phase II study have solidified a path forward for pertuzumab plus trastuzumab in HER2-positive colorectal cancer patients.

Geneoscopy Closes $105M Series B Financing Round

The company said it will use the funds in part to support a study of ColonoSight, its multi-target stool RNA test for colorectal screening.

Nov 8, 2021

German MDx Firm Mainz Biomed Raises $10M in IPO, Begins Trading on Nasdaq

Nov 5, 2021

Natera Aiming to Translate Success in Colorectal Cancer Diagnostics Into Other Areas
Premium

Nov 3, 2021

Exact Sciences Gearing up for Busy 2022, Beyond
Premium

Oct 27, 2021

Joint Venture From SEngine, Gustave Roussy Aims to Commercialize Cancer Dx Test Across Europe
Premium

Oct 15, 2021

Natera Builds Data Backing Serial ctDNA Changes to Aid CRC Patient Management, Treatment Decisions
Premium

Sep 14, 2021

Exact Sciences, NSABP Validating Ability of ctDNA Test to Detect MRD in Colorectal Cancer Patients

Aug 18, 2021

FDA Approves GlaxoSmithKline's Jemperli, Roche’s Ventana CDx for dMMR Solid Cancers

Aug 6, 2021

Guardant Health Laying Path for Future in Cancer Screening, Updates Launch Plans for CRC Assay
Premium

Aug 5, 2021

Pillar Biosciences Receives FDA Approval for OncoReveal Dx Lung and Colon Cancer Assay

Jul 22, 2021

Natera Minimal Residual Disease Test Predicts Oligometastatic CRC Patient Outcomes in New Study
Premium

Jul 14, 2021

Geneoscopy Enrolls Patients in Pivotal Trial for Colorectal Cancer Dx Approval
Premium

Jun 3, 2021

Oncocyte, Italian Foundation to Investigate DetermaIO in Colorectal Cancer

May 18, 2021

USPSTF Now Recommends Colorectal Cancer Screening Beginning at Age 45

May 7, 2021

Guardant MRD Test Performs Well in Small Study as Tissue-Informed Debate Takes Shape
Premium

Apr 30, 2021

Aiming to Cut Unnecessary Surgeries, City of Hope Team to Commercialize CRC Metastasis Dx Signature
Premium

Apr 20, 2021

Biocartis Files FDA Submission for Microsatellite Instability Test in Colorectal Cancer

Apr 1, 2021

Guardant Health Receives New York State Approval for Guardant Reveal MRD Test

Mar 25, 2021

Epigenomics Reports 24 Percent Drop in 2020 Revenues, Seeks Sale After Negative Coverage Decision

Mar 23, 2021

CellMax Life, Sebela Pharmaceuticals Sign Commercial Agreement for Colorectal Cancer Dx Test

Mar 12, 2021

GeneFirst Aims to Prove Clinical Feasibility for ATOM-Seq Colorectal Cancer Detection Test
Premium